254 related articles for article (PubMed ID: 30644386)
1. Breakdown of adaptive immunotolerance induces hepatocellular carcinoma in HBsAg-tg mice.
Zong L; Peng H; Sun C; Li F; Zheng M; Chen Y; Wei H; Sun R; Tian Z
Nat Commun; 2019 Jan; 10(1):221. PubMed ID: 30644386
[TBL] [Abstract][Full Text] [Related]
2. HBV immune tolerance of HBs-transgenic mice observed through parabiosis with WT mice.
Zhang W; Sun H; Sun R; Lian Z; Wei H; Tian Z; Chen Y
Front Immunol; 2022; 13():993246. PubMed ID: 36203595
[TBL] [Abstract][Full Text] [Related]
3. PD-1
Liu X; Li M; Wang X; Dang Z; Jiang Y; Wang X; Kong Y; Yang Z
Cancer Immunol Immunother; 2019 Dec; 68(12):2041-2054. PubMed ID: 31720814
[TBL] [Abstract][Full Text] [Related]
4. CD137-mediated pathogenesis from chronic hepatitis to hepatocellular carcinoma in hepatitis B virus-transgenic mice.
Wang J; Zhao W; Cheng L; Guo M; Li D; Li X; Tan Y; Ma S; Li S; Yang Y; Chen L; Wang S
J Immunol; 2010 Dec; 185(12):7654-62. PubMed ID: 21059892
[TBL] [Abstract][Full Text] [Related]
5. HBsAg-specific CD8
Hao X; Chen Y; Bai L; Wei H; Sun R; Tian Z
Cell Mol Immunol; 2021 Jan; 18(1):128-137. PubMed ID: 31767976
[TBL] [Abstract][Full Text] [Related]
6. Inducing oral immune regulation of hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice.
Gotsman I; Alper R; Klein A; Rabbani E; Engelhardt D; Ilan Y
Cancer; 2002 Jan; 94(2):406-14. PubMed ID: 11900226
[TBL] [Abstract][Full Text] [Related]
7. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
8. Role of Immune Cells in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma.
Cho HJ; Cheong JY
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360777
[TBL] [Abstract][Full Text] [Related]
9. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3-ITGB1 Signaling Mediates Interleukin 10 Production of Hepatic Conventional Natural Killer Cells in Hepatitis B Virus Transgenic Mice and Correlates with Hepatocellular Carcinoma Progression in Patients.
Chen Y; Zhang W; Cheng M; Hao X; Wei H; Sun R; Tian Z
Viruses; 2024 May; 16(5):. PubMed ID: 38793619
[TBL] [Abstract][Full Text] [Related]
12. Breaking tolerance in hepatitis B surface antigen (HBsAg) transgenic mice by vaccination with cross-reactive, natural HBsAg variants.
Schirmbeck R; Dikopoulos N; Kwissa M; Leithäuser F; Lamberth K; Buus S; Melber K; Reimann J
Eur J Immunol; 2003 Dec; 33(12):3342-52. PubMed ID: 14635042
[TBL] [Abstract][Full Text] [Related]
13. Blockade of T-cell receptor with Ig and ITIM domains elicits potent antitumor immunity in naturally occurring HBV-related HCC in mice.
Wu Y; Hao X; Wei H; Sun R; Chen Y; Tian Z
Hepatology; 2023 Mar; 77(3):965-981. PubMed ID: 35938354
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro.
Shi M; Qian S; Chen WW; Zhang H; Zhang B; Tang ZR; Zhang Z; Wang FS
Clin Exp Immunol; 2007 Feb; 147(2):277-86. PubMed ID: 17223969
[TBL] [Abstract][Full Text] [Related]
15. Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice.
Wang X; Dong A; Xiao J; Zhou X; Mi H; Xu H; Zhang J; Wang B
Cell Mol Immunol; 2016 Nov; 13(6):850-861. PubMed ID: 26166767
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine.
Zhou C; Peng G; Jin X; Tang J; Chen Z
Clin Immunol; 2010 Nov; 137(2):190-8. PubMed ID: 20692873
[TBL] [Abstract][Full Text] [Related]
17. Breaking Hepatitis B Virus Tolerance and Inducing Protective Immunity Based on Mimicking T Cell-Independent Antigen.
Li X; Ni R
Viral Immunol; 2016 Nov; 29(9):502-509. PubMed ID: 27662269
[TBL] [Abstract][Full Text] [Related]
18. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.
Lim CJ; Lee YH; Pan L; Lai L; Chua C; Wasser M; Lim TKH; Yeong J; Toh HC; Lee SY; Chan CY; Goh BK; Chung A; Heikenwälder M; Ng IO; Chow P; Albani S; Chew V
Gut; 2019 May; 68(5):916-927. PubMed ID: 29970455
[TBL] [Abstract][Full Text] [Related]
19. Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance.
Willimsky G; Schmidt K; Loddenkemper C; Gellermann J; Blankenstein T
J Clin Invest; 2013 Mar; 123(3):1032-43. PubMed ID: 23454765
[TBL] [Abstract][Full Text] [Related]
20. IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier.
Zeng Z; Kong X; Li F; Wei H; Sun R; Tian Z
J Immunol; 2013 Oct; 191(8):4184-93. PubMed ID: 24048897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
